Net Profit Margin
since 2005
Beginner level
Calculation
Regeneron Pharmaceuticals Inc., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income (loss)1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2019 | 26.91% | = | 100 | × | 2,115,800 | ÷ | 7,863,400 |
| Dec 31, 2018 | 36.42% | = | 100 | × | 2,444,400 | ÷ | 6,710,800 |
| Dec 31, 2017 | 20.41% | = | 100 | × | 1,198,511 | ÷ | 5,872,227 |
| Dec 31, 2016 | 18.42% | = | 100 | × | 895,522 | ÷ | 4,860,427 |
| Dec 31, 2015 | 15.50% | = | 100 | × | 636,056 | ÷ | 4,103,728 |
| Dec 31, 2014 | 12.34% | = | 100 | × | 348,074 | ÷ | 2,819,557 |
| Dec 31, 2013 | 20.16% | = | 100 | × | 424,362 | ÷ | 2,104,745 |
| Dec 31, 2012 | 54.43% | = | 100 | × | 750,269 | ÷ | 1,378,477 |
| Dec 31, 2011 | -49.74% | = | 100 | × | (221,760) | ÷ | 445,824 |
| Dec 31, 2010 | -22.76% | = | 100 | × | (104,468) | ÷ | 459,074 |
| Dec 31, 2009 | -17.88% | = | 100 | × | (67,830) | ÷ | 379,268 |
| Dec 31, 2008 | -34.69% | = | 100 | × | (82,710) | ÷ | 238,457 |
| Dec 31, 2007 | -84.46% | = | 100 | × | (105,600) | ÷ | 125,024 |
| Dec 31, 2006 | -161.30% | = | 100 | × | (102,337) | ÷ | 63,447 |
| Dec 31, 2005 | -144.19% | = | 100 | × | (95,446) | ÷ | 66,193 |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).
1 US$ in thousands
Comparison to Competitors
Regeneron Pharmaceuticals Inc., net profit margin, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | Abbott Laboratories | AbbVie Inc. | Allergan PLC | Amgen Inc. | Biogen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Illumina Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Vertex Pharmaceuticals Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2019 | 26.91% | 11.56% | 23.69% | -32.76% | 35.32% | 40.96% | 13.15% | 37.27% | 24.35% | 28.28% | 18.42% | 21.01% | 31.45% | 28.27% | 23.96% |
| Dec 31, 2018 | 36.42% | 7.74% | 17.36% | -32.28% | 37.25% | 32.93% | 21.81% | 13.16% | 25.16% | 24.78% | 18.75% | 14.71% | 20.79% | 68.80% | 24.52% |
| Dec 31, 2017 | 20.41% | 1.74% | 18.82% | -25.88% | 9.08% | 20.69% | 4.85% | -0.89% | 18.03% | 26.38% | 1.70% | 5.97% | 40.55% | 10.59% | 16.28% |
| Dec 31, 2016 | 18.42% | 6.71% | 23.22% | 102.76% | 35.27% | 32.34% | 22.94% | 12.90% | 45.07% | 19.29% | 23.01% | 9.85% | 13.66% | -6.58% | 16.80% |
| Dec 31, 2015 | 15.50% | 21.68% | 22.50% | 25.98% | 33.13% | 32.95% | 9.45% | 12.07% | 56.32% | 20.79% | 21.99% | 11.25% | 14.25% | -53.89% | 7.11% |
| Dec 31, 2014 | 12.34% | 11.28% | 8.89% | -12.48% | 26.69% | 30.25% | 12.62% | 12.19% | 49.44% | 18.98% | 21.96% | 28.22% | 18.42% | -127.25% | 12.18% |
| Dec 31, 2013 | 20.16% | 11.79% | 21.97% | -8.65% | 27.93% | 26.87% | 15.64% | 20.27% | 28.46% | 8.82% | 19.40% | 10.00% | 42.65% | -36.72% | 11.05% |
| Dec 31, 2012 | 54.43% | 14.95% | 28.70% | 1.64% | 26.11% | 25.02% | 11.12% | 18.09% | 27.57% | 13.17% | 16.14% | 13.05% | 24.70% | -7.01% | 10.06% |
| Dec 31, 2011 | -49.74% | 12.17% | — | 5.69% | 24.08% | 24.45% | 17.46% | 17.90% | 34.60% | 8.21% | 14.87% | 13.05% | 14.84% | 2.10% | — |
| Dec 31, 2010 | -22.76% | 13.15% | — | 5.17% | 31.56% | 21.31% | 15.92% | 21.97% | 39.26% | 13.83% | 21.65% | 1.87% | 12.18% | -526.35% | — |
| Dec 31, 2009 | -17.88% | 18.68% | — | 7.95% | 32.09% | 22.16% | 56.42% | 19.82% | 40.74% | 10.85% | 19.82% | 47.04% | 17.27% | -630.27% | — |
| Dec 31, 2008 | -34.69% | 16.53% | — | 9.40% | 28.57% | 19.11% | 25.47% | -10.17% | 39.55% | 8.81% | 20.31% | 32.74% | 16.78% | -262.02% | — |
| Dec 31, 2007 | -84.46% | 13.92% | — | 5.65% | 22.12% | 20.12% | 11.19% | 15.85% | 43.27% | -75.89% | 17.31% | 13.54% | 16.82% | -196.61% | — |
| Dec 31, 2006 | -161.30% | 7.64% | — | -22.48% | 21.29% | 8.11% | 8.85% | 16.97% | -45.98% | 21.65% | 20.73% | 19.59% | 39.98% | -95.63% | — |
| Dec 31, 2005 | -144.19% | 15.10% | — | 8.40% | 30.56% | 6.63% | 15.62% | 13.52% | 44.99% | -28.40% | 20.61% | 21.04% | 15.76% | -126.43% | — |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).
Comparison to Sector (Pharmaceuticals & Biotechnology)
Regeneron Pharmaceuticals Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals & biotechnology)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2019 | 26.91% | 21.54% |
| Dec 31, 2018 | 36.42% | 18.10% |
| Dec 31, 2017 | 20.41% | 11.00% |
| Dec 31, 2016 | 18.42% | 24.52% |
| Dec 31, 2015 | 15.50% | 22.40% |
| Dec 31, 2014 | 12.34% | 20.39% |
| Dec 31, 2013 | 20.16% | 21.29% |
| Dec 31, 2012 | 54.43% | 18.41% |
| Dec 31, 2011 | -49.74% | 15.50% |
| Dec 31, 2010 | -22.76% | 15.17% |
| Dec 31, 2009 | -17.88% | 25.96% |
| Dec 31, 2008 | -34.69% | 18.67% |
| Dec 31, 2007 | -84.46% | 15.99% |
| Dec 31, 2006 | -161.30% | 20.82% |
| Dec 31, 2005 | -144.19% | 18.13% |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., net profit margin, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Dec 31, 2019 | 26.91% | 15.78% |
| Dec 31, 2018 | 36.42% | 13.31% |
| Dec 31, 2017 | 20.41% | 9.28% |
| Dec 31, 2016 | 18.42% | 16.45% |
| Dec 31, 2015 | 15.50% | 15.70% |
| Dec 31, 2014 | 12.34% | 15.13% |
| Dec 31, 2013 | 20.16% | 16.06% |
| Dec 31, 2012 | 54.43% | 14.04% |
| Dec 31, 2011 | -49.74% | 13.14% |
| Dec 31, 2010 | -22.76% | 12.60% |
| Dec 31, 2009 | -17.88% | 18.63% |
| Dec 31, 2008 | -34.69% | 13.81% |
| Dec 31, 2007 | -84.46% | 13.30% |
| Dec 31, 2006 | -161.30% | 15.18% |
| Dec 31, 2005 | -144.19% | 15.79% |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12), 10-K (filing date: 2014-02-13), 10-K (filing date: 2013-02-15), 10-K (filing date: 2012-02-21), 10-K (filing date: 2011-02-17), 10-K (filing date: 2010-02-18), 10-K (filing date: 2009-02-26), 10-K (filing date: 2008-02-27), 10-K (filing date: 2007-03-12), 10-K (filing date: 2006-02-28).